Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN Podcasts

*Podcasts play in a pop-up window. Please make sure your pop-up blocker is off.

GEN’s editorial staff interviews life science academic and biotech industry leaders on important research, technology, and trends. These podcasts will keep you informed with all the important details you need.

A team at The Scripps Research Institute reports that it has made major strides in solving a problem that has been plaguing chemists for many years: how best to break carbon-hydrogen bonds and then to create new bonds to join molecules together. This problem is of great importance to the pharmaceutical industry, which currently relies on a method to accomplish this feat that is relatively inefficient and sometimes difficult to perform.

The research was published online on November 26, 2009, in Science Express.

During this week's podcast, team leader Dr. Jin-Quan Yu provides additional details on the pharmaceutical industry's interest in carbon-hydrogen bonds. He discusses the advantages, and the downside, of relying on the "Mizoroki-Heck" reaction, which is currently used by chemists and pharmaceutical scientists to forge carbon-carbon bonds in place of carbon-hydrogen bonds.

Dr. Yu goes on to describe the new technique his team developed to break carbon-hydrogen bonds more efficiently and economically and how it might impact the discovery, development, and manufacture of novel drug compounds.
Jin-Quan Yu, Ph.D. is an Associate Professor in the Department of Chemistry at the Scripps Research Institute.

  • Add a comment

  • Click here to Login/Register for free. You will be taken back to your selected item after Login/Registration.

Related content

Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »